FINWIRES · TerminalLIVE
FINWIRES

美国银行称,数据中心和人工智能领域的半导体需求将被汽车和消费品行业的需求所抵消。

By

-- 美国银行证券分析师周一在一份报告中指出,半导体股票的需求环境喜忧参半,数据中心和人工智能领域相对强劲,但传统汽车和消费品行业表现疲软,抵消了部分需求。 分析师表示,他们更青睐自由现金流强劲的公司。他们在该行业的大型公司中首选Analog Devices (ADI),而中小型公司中的首选是MACOM Technology Solutions (MTSI)。 美国银行将安森美半导体(ON Semiconductor)的评级从“中性”上调至“买入”,并将目标价从70美元上调至85美元。分析师强调了该股的研发管线、“稳健”的自由现金流、股票回购承诺、模型杠杆率以及较低的资产负债表杠杆率。 对于恩智浦半导体(NXP Semiconductors),分析师将评级从“买入”下调至“中性”,并将目标价从245美元下调至230美元,指出在模拟半导体行业竞争日益激烈的环境下,该股与同行相比“吸引力有所下降”。 美国银行维持对Analog Devices的“买入”评级,并将目标价从400美元上调至425美元,以反映其在人工智能等核心长期增长领域的增长势头。 分析师也维持对MACOM Technology Solutions的“买入”评级,并将目标价从260美元上调至305美元,原因是该公司在光学行业的持续增长势头。

Price: $70.19, Change: $+1.54, Percent Change: +2.24%

Related Articles

Treasury

Scotiabank Previews This Week's February and Preliminary March GDP for Canada

Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.

$$CXY
Australia

Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing

Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%

$VICR
Australia

BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%

$BMRN$FOLD